1. Effects of capecitabine chemotherapy on the expression of CASC18, CASC19, and CASC20 lncRNAs in patients with colorectal cancer and the HCT-116 colorectal cancer cell line
- Author
-
Nafea M. Chayd, Mohammad Khalaj-Kondori, Reza Safaralizadeh, and Mohammad Ali Hosseinpour Feizi
- Subjects
Pharmacy and materia medica ,RS1-441 - Abstract
Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths. Capecitabine is a key chemotherapy drug for colorectal cancer (CRC). Long non-coding RNAs (lncRNAs) play a role in the pathogenic pathways associated with colorectal cancer. This investigation compared the expression patterns of CASC18, CASC19, and CASC20 in CRC patients before and after chemotherapy, as well as in healthy individuals. The effects of capecitabine on cell viability, apoptosis, cell cycle, and the expressions of CASC18, CASC19, and CASC20 were examined using HCT-116 cells. Methods: CASC18, CASC19, and CASC20 expressions were assessed using qRT-PCR on patients’ and healthy tissues. Furthermore, the receiver operating characteristic (ROC) curve analysis was used to evaluate the prognostic and diagnostic value of CASC18, CASC19, and CASC20 in CRC. The MTT test was used to assess capecitabine’s cytotoxicity on the HCT-116 CRC cell line. Annexin-V/PI staining was used to examine apoptosis and cell cycle progression by flow cytometry. Gene expression differences between before and after capecitabine treatments were examined by qRT-PCR. Results: Results showed that patients with colorectal cancer had lower levels of CASC18 but higher levels of CASC19 and CASC20 expression than the healthy group. Moreover, patients treated with capecitabine showed an increased CASC18 expression, while non-significant changes were observed in the expression of CASC19 and CASC20. The clinical factors were not associated with the expression of lncRNAs CASC18, CASC19, and CASC20. Furthermore, results indicated that CASC18, CASC19, and CASC20 are poor biomarkers for diagnosis of CRC. MTT analysis revealed a dose- and time-dependent cytotoxic effect for capecitabine on the HCT-116 cells. Capecitabine treatment led to the accumulation of the HCT-116 cells in the Sub-G1 phase, suggesting an apoptotic solid impact on the cells. Moreover, HCT-116 cells were arrested in the G2/M phases by capecitabine. Capecitabine also upregulated CASC18 expression in the HCT-116 cell line. Conclusion: These results support the anticancer and cytotoxic effects of capecitabine and highlight its ability to increase CASC18 expression. Additionally, the findings indicate that CASC18, CASC19, and CASC20 are poor biomarkers for colorectal cancer (CRC) diagnosis.
- Published
- 2025
- Full Text
- View/download PDF